Dr James McIlroy MBChB BMedSci (Hons)
Entrepreneur | Medical Doctor | Speaker
Developing and advancing bio-pharmaceutical innovations to sustain and improve human health.
My work has been instrumental in translating human intestinal microbiome transfer from an unregulated research topic into a regulated industry and clinical practice.
I founded EnteroBiotix after recognising the therapeutic potential of the microbiome with the vision of building one of the world’s leading microbiome drug development companies. As CEO, I work to combine scientific, medical, and business expertise to effectively lead our drug development programmes.
I have over 5 years of leadership experience as a biopharmaceutical entrepreneur, Board Director and company executive, with hands on experience in creating, building and successfully leading cross-functional teams that have delivered significant value building milestones for shareholders. I have successfully raised multiple rounds of equity investment with deal values in excess of £10m to pioneer the application of GMP to intestinal microbiome material. I have also secured multiple large grant funding awards from high-profile funding bodies such as the Medical Research Council and Innovate UK.
I am a qualified medical doctor that has successfully completed training posts with the UK National Health Service in multiple hospital service areas including: Acute Internal Medicine, General Surgery and Medical Paediatrics. I hold a BMedSci (Hons) from the University of Edinburgh and an MBChB from the University of Aberdeen, graduating with a final year distinction (top 3% of year) and the elective prize in child health awarded in recognition of my published research on intestinal microbiome modulation in paediatric patient populations.
I was the first undergraduate to be awarded an Enterprise Fellowship by the royal Society of Edinburgh and I am the youngest recipient of a Visiting Research Fellowship by United European Gastroenterology. I am currently appointed as honorary Lecturer in Healthcare Innovation at the University of Aberdeen, Advisory Board member at Innovate UK/KTN Microbiome Special Interest Group and Co-Founder of the Intestinal Microbiome-based Medicines European Task Group (IMM-ETG).
I am named inventor on several microbiome related patent applications and have been published as first author in journals such as Alimentary Pharmacology & Therapeutics, Frontline Gastroenterology and Clinical Immunology.